Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$890.38 USD

890.38
619,804

+5.90 (0.67%)

Updated Oct 2, 2024 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?

Smart Beta ETF report for XPH

    Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN

    Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.

      Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

      Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

        Top Ranked Growth Stocks to Buy for April 20th

        Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 20th:

          Amgen's Aimovig Reduces Episodic Migraine in 30% Patients

          Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.

            5 Drug Stocks Poised to Surpass on Earnings This Quarter

            The outlook for the upcoming first-quarter results looks bright.

              Merck's Keytruda Betters Survival in Lung Cancer Combo Study

              Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.

                Celldex's Phase II Breast Cancer Study Fails, Shares Plunge

                Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.

                  Merck's Keytruda Reduces Death Risk in Melanoma Patients

                  Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.

                    AbbVie's RA Candidate Meets Primary Endpoints in Phase III

                    AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.

                      vTv Therapeutics Crashes on Alzheimer's Drug Study Failure

                      vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.

                        Merck's Keytruda Offers Survival Benefit in Lung Cancer Study

                        Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.

                          Kinjel Shah headshot

                          Novartis and Other Drug Stocks With FDA Catalysts in April

                          With just a quarter gone by this year, the FDA has already granted approval to six new treatments.

                            Top Ranked Growth Stocks to Buy for April 10th

                            Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 10th:

                              Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study

                              A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.

                                FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus

                                The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.

                                  Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year

                                  ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.

                                    FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy

                                    Bristol-Myers' (BMY) filing for Opdivo in combination with Yervoy gains acceptance from the FDA for treating metastatic colorectal cancer. A response is expected in July, 2018.

                                      The Zacks Analyst Blog Highlights: Nike, Eli Lilly, NVIDIA, L Brands and Alleghany

                                      The Zacks Analyst Blog Highlights: Nike, Eli Lilly, NVIDIA, L Brands and Alleghany

                                        Roche's Tecentriq Combo Study Meets Co-Primary Endpoint

                                        Roche's (RHHBY) phase III study, evaluating a combination of Tecentriq and Avastin plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of overall survival.

                                          Pfizer's Chantix Fails in Phase IV Study in Young Smokers

                                          Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.

                                            Radius Health Down on Negative CHMP Opinion for Lead Drug

                                            Shares of Radius Health (RDUS) declined after the company's application for lead drug, abaloparatide-SC, was given a negative opinion by the CHMP in Europe.

                                              Merck Gets European Committee Vote for Veterinary Product

                                              Merck (MRK) is seeking approval of Bravecto Plus, a spot-on solution for cats. The drug is part of the company's Animal Health unit.

                                                Swarup Gupta headshot

                                                Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks

                                                Industry watchers have grown skeptical about Trump's intermittent pronouncements on this issue.

                                                  Roche Tecentriq Phase III Combo Study Meets Primary Endpoint

                                                  Roche (RHHBY) announces that the combination study of Tecentriq plus chemotherapy meets its co-primary endpoint of progression-free survival.